BioSpace News Archive

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced it is commercially launching its Omnipod DASH® Insulin Management System in additional countries.

Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, announced that Health Canada has approved its next generation rechargeable implantable neurostimulator for the Axonics r-SNM® System.

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announced the results of the final overall survival analysis from its global Phase 3 ClarIDHy trial of TIBSOVO® in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation.

Live presentation highlightingTRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting

Increasing BCMA Surface Expression and Reduced Soluble BCMA Levels with Gamma Secretase Inhibitor Nirogacestat May Enhance Clinical Benefit in Combination with PBCAR269A, an Allogeneic BCMA-Targeted CAR T Cell Product

Cend Therapeutics, Inc., a clinical-stage biotech company, announced that it has acquired Impilo Therapeutics, Inc.

Algiax Pharmaceuticals, a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need, announced that the first patient has been enrolled in the “CURE” study.

BIOLIFE4D, a biotech pioneer leveraging advances in tissue engineering to 3D print human organs viable for transplant, today announced it has named Kate Lewis as President of the company.

Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced the appointments of Caroline M. Loewy, Mary E. Stutts and Denelle J. Waynick to newly created seats on its Board of Directors, effective immediately.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has cleared the Investigational New Drug (IND) application for lemzoparlimab